[HTML][HTML] Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study
U Mrowietz, H Bachelez, AD Burden, M Rissler… - Journal of the American …, 2019 - Elsevier
Background Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms
and/or soles that is resistant to treatment. Secukinumab, an anti–interleukin 17A monoclonal
antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis. Objective
The primary objective was to determine the rate of achievement of a 75% improvement from
baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI75) with secukinumab
at week 16 versus with placebo (at a 2.5% significance level). Methods 2PRECISE was a …
and/or soles that is resistant to treatment. Secukinumab, an anti–interleukin 17A monoclonal
antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis. Objective
The primary objective was to determine the rate of achievement of a 75% improvement from
baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI75) with secukinumab
at week 16 versus with placebo (at a 2.5% significance level). Methods 2PRECISE was a …
